Immunotherapy of Brain Cancers and Neurological Disorders

Fymat, A. L.

doi:10.15406/jcpcr.2017.08.00301

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to chemotherapy, I have again briefly reviewed the other treatment strategies that are used either singly or in combination with chemotherapy, including: surgery; conformal radiotherapy; boron neutron therapy; intensity modulated proton beam therapy; Antiangiogenic therapy; alternating electric fields; and even vaccines and palliative therapies and lifestyle changes [21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenic Targeting of Early Developing Glioblastoma Behind a Weakened Blood Brain Barrier

Fymat

2017

JTMP

View full text Add to dashboard Cite

Glioblastoma is the most devastating and most common brain tumor in adults. According to the (US) National Cancer Institute (NCI), there were an estimated 23,380 new cases and 14,320 deaths from brain and other nervous system cancers in the US in 2014. I will emphasize here therapy using Antiangiogenic agents, particularly in the case of tumors in their early development, taking advantage of the associated weakening of the blood brain barrier. As a prelude to this new development, I review below the current lines of treatment for Glioblastoma, making a distinction between primary and secondary tumors, and recurrent tumors. I will also review the brain protective barriers, chiefly the blood brain barrier which, as its name implies, is the primary impediment for the delivery of therapeutic drugs. I will also analyze the drug targeting difficulties and the mechanisms for drug targeting.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiangiogenic Targeting of Early Developing Glioblastoma Behind a Weakened Blood Brain Barrier

Fymat

2017

JTMP

View full text Add to dashboard Cite

show abstract

“…The application of immunotherapy in the case of brain cancers has been discussed elsewhere [42][43][44].…”

Section: Immunotherapymentioning

confidence: 99%

Surgical and Non-Surgical Management and Treatment of Glioblastoma: I. Primary Tumors

Fymat¹

2017

OAJS

Self Cite

View full text Add to dashboard Cite

Glioblastoma, the most common primary brain tumor in adults, remains an unmet need in oncology. Its management and treatment begin with an understanding of this tumor's morphology, biological types, risk factors, and prognosis. The various surgical and non-surgical modalities devised so far for primary tumors and their metastases are presented and discussed either singly or in combination. For each such therapy, the treatment results obtained in clinical trials and other reported practices are also summarized and discussed. Historically, chemotherapy has provided little durable benefit with tumors recurring within several months, even in the case of more accessible tumors located outside the brain, let alone within the brain behind its protective barriers. More effective therapies involving other options are required either in isolation or more likely in combination. Of these other options, the following are considered here at some length: surgery, conformal radiotherapy, boron neutron therapy, intensity modulated proton beam therapy, antiangiogenic therapy, alternating electric field therapy, immunotherapy without neglecting palliative therapies. A companion paper will discuss the important case of recurring tumors.

show abstract

“…There is aggressiveness, crying, or anger. [7][8] In clinical practice, behavioral and psychiatric disorders exhibit a variety of cognitive and noncognitive symptoms. Patients ultimately develop behavioral or psychiatric symptoms in over 90% of the cases of dementia.…”

Section: Introductionmentioning

confidence: 99%

Hematological Profile of Patients with Dementia in South Punjab

et al. 2021

View full text Add to dashboard Cite

Objectives: A case-control study was conducted to find the prevalence of abnormal blood indices and electrolytes in patients with dementia. Material & Methods: The levels of erythrocytes, leukocytes, platelets, electrolytes, and ESR were determined from the biochemistry lab. A t-test was applied to see the significance of the difference between each dementia patient group (Alzheimer Disease-AD, Parkinson’s Disease-PD, and Frontotemporal Dementia-FTD) with the control group for each CBC and electrolyte parameter Results: In each patients’ groups (AD, PD, and FTD), the mean value of every erythrocyte was lower than the normal range. A significant difference existed for each erythrocyte between dementia patients and controls, except MCHC. Low levels were observed in neutrophils in all groups of dementia including control group. Very high levels were observed in ESR in all groups of dementia. Significant differences existed in the WBC levels between controls and AD as well as PD patients, in platelets between the control group and FTD patients, and in ESR in each group of dementia patients vs. control group. Normal values observed in all groups of dementia patients as well as in the control group. Conclusion: We found low levels in erythrocytes in cases of Alzheimer disease, Parkinson’s disease, and frontotemporal dementia. Age-related changes to hematological indices especially related to RBCs, and inflammatory mediators like cytokines, hamper the microcirculation in the cerebral tissue leading to micro-infarcts or microbleeds which cause neuronal insults and parenchymal damage.

show abstract

Immunotherapy of Brain Cancers and Neurological Disorders

Cited by 3 publications

References 24 publications

Antiangiogenic Targeting of Early Developing Glioblastoma Behind a Weakened Blood Brain Barrier

Antiangiogenic Targeting of Early Developing Glioblastoma Behind a Weakened Blood Brain Barrier

Surgical and Non-Surgical Management and Treatment of Glioblastoma: I. Primary Tumors

Hematological Profile of Patients with Dementia in South Punjab

Contact Info

Product

Resources

About